These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19634508)

  • 1. Proton pump inhibitors--their pharmacological impact on the clinical management of acid-related disorders.
    Klotz U
    Arzneimittelforschung; 2009; 59(6):271-82. PubMed ID: 19634508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitors: an update of their clinical use and pharmacokinetics.
    Shi S; Klotz U
    Eur J Clin Pharmacol; 2008 Oct; 64(10):935-51. PubMed ID: 18679668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors: actions and reactions.
    Mullin JM; Gabello M; Murray LJ; Farrell CP; Bellows J; Wolov KR; Kearney KR; Rudolph D; Thornton JJ
    Drug Discov Today; 2009 Jul; 14(13-14):647-60. PubMed ID: 19443264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
    Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
    Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
    Robinson M; Horn J
    Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.
    Thjodleifsson B
    Drugs Aging; 2002; 19(12):911-27. PubMed ID: 12495367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology of esomeprazole and its role in gastric acid related diseases.
    Saccar CL
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1113-24. PubMed ID: 19606942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
    Mullner K; Molnar B; Tulassay Z
    Orv Hetil; 2007 Mar; 148(12):543-51. PubMed ID: 17444020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in chirally pure proton pump inhibitors.
    Pai V; Pai N
    J Indian Med Assoc; 2007 Aug; 105(8):469-70, 472, 474. PubMed ID: 18236913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibition. An effective, safe approach to GERD management.
    Berardi RR
    Postgrad Med; 2001 Oct; Spec No():24-35. PubMed ID: 11868428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
    Kirchheiner J; Glatt S; Fuhr U; Klotz U; Meineke I; Seufferlein T; Brockmöller J
    Eur J Clin Pharmacol; 2009 Jan; 65(1):19-31. PubMed ID: 18925391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
    Blume H; Donath F; Warnke A; Schug BS
    Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical considerations in the management of proton-pump inhibitors.
    Aguilera-Castro L; Martín-de-Argila-dePrados C; Albillos-Martínez A
    Rev Esp Enferm Dig; 2016 Mar; 108(3):145-53. PubMed ID: 26666270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic options in the treatment of GERD and other acid-peptic disorders. Based on a presentation by Duane D. Webb, MD, FACG.
    Am J Manag Care; 2000 May; 6(9 Suppl):S467-75. PubMed ID: 10977486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
    Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.